To deliver its gene therapy to the inner ear, Decibel Therapeutics adapted the existing, well-understood surgical procedure for cochlear implants. This strategy de-risked the novel therapeutic by leveraging a proven delivery technique and existing surgical expertise, avoiding the need to invent an entirely new procedure.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

Regeneron's RGC is exploring a new business model beyond its internal R&D function. It plans to partner with direct-to-consumer (DTC) platforms to bring its genomic insights on health and wellness directly to patients, signaling an evolution from a pure data engine to a broader life sciences intelligence player.

Instead of only seeking disease-causing genes, Regeneron's primary strategy is to find rare protective mutations in individuals they call "superhumans." These people, naturally protected from diseases like heart attacks, provide a validated blueprint for new drugs. The company has already found over 50 such protective factors.

Regeneron identified the main constraint in drug discovery as a lack of validated targets, not a shortage of advanced therapeutic tools. Their genetics engine was created to explore the 90% of the human genome that was untargeted by existing or experimental medicines, aiming to solve this core problem.

Regeneron's Genetics Center is a key competitive advantage, functioning as a discovery engine for new drug targets. By sequencing millions of patient genomes and linking them to health records, it allows Regeneron to identify novel genetic variants associated with diseases, feeding its antibody development pipeline with proprietary targets.

Instead of traditional methods, Regeneron sequences millions of people to find "superhumans"—those with rare genetic mutations that protect them from diseases. By studying these individuals, they identify high-confidence drug targets that mimic these natural protections, aiming for a higher probability of success in development.

Regeneron systematically expands the market for its drugs through "indication expansion." By identifying people in its database with a natural loss-of-function variant for a drug's target, they can scan thousands of diseases to see what other conditions these people are protected from, revealing new therapeutic opportunities.

While the industry success rate for drugs entering the clinic is only about 10%, programs with human genetics backing have a 2-3x higher probability of approval. Regeneron reports its success rate is even higher, at four to five times the baseline, due to its strict focus on large-effect genetic signals.